Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

UNITED STATES: FDA Approves First Anti-Diarrheal Drug for HIV/AIDS Patients




 

FDA News Release (12.31.12) Aids Weekly Plus

On December 31, the US Food and Drug Administration approved Fulyzaq (Crofelemer) to treat diarrhea symptoms in HIV/AIDS patients currently on antiretroviral therapy (ART). Many ART patients either change or discontinue their therapies because of the resultant diarrhea. Fulyzaq is intended for HIV/AIDS patients whose diarrhea is not caused by infection from a virus, bacteria, or parasite. Derived from the red sap of the Croton lechleri plant, Fulyzaq is only the second botanical prescription drug approved by the FDA—a botanical drug can be a complex mixture derived from one or more plant materials of varying degrees of purity. Currently, there are no other FDA-approved therapies for HIV-associated diarrhea, according to Julie Beitz, MD, director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research.



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in January 2, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.